Clinical trial · no report yet · Phase 2
PemCab
Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma
- NCT03534804 ↗
- Completed
- University of Utah
- 18 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 14 | |
| YouTube | 3 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Metastatic Urothelial Carcinoma; Bladder Cancer
- Interventions
- Cabozantinib; Pembrolizumab
- Arms
- Cabozantinib and Pembrolizumab, all patients · Experimental
- Enrollment
- 37
- Primary outcomes
- Count of Participants With Response Measured by RECIST 1.1
- Sponsor
- University of Utah with Exelixis
- Start
- Sep 18, 2018
- Primary completion
- Aug 2, 2023
- Results posted
- Yes
- Registry record
- NCT03534804 · updated Nov 26, 2024